MedTech Forum 2019: Consumers And Wellness, Or Patients And Health Care?

Medtech's Future Hinges On How The Sector Can Change With The Times

As health care transitions to digitally enabled wellness, medtechs will be missing a trick if they persist in holding onto the delivery, business methods and models that were the standard of the early 2000s. Heightened expectations of the new options for dealing with personal health mean that new opportunities are there for the taking – but industry shouldn’t let the tech companies have it all their own way, advised ZS principal Brian Chapman.

The MedTech Forum, Medtech Europe’s annual conference, was uprooted for the first time in its history, shifting from Brussels to Paris for 2019. The change of location worked well: by tacking the already populous event onto the back of the French industry association's (Snitem) annual start-ups forum (Journée Start-up innovantes du dispostif médical) attendee numbers swelled nicely. (Also see "French Minister Has Her Own Angle On the Success Of Medtech" - Medtech Insight, 30 May, 2019.)

And the French delegates offered fresh ideas on innovation and uptake, and especially on digital innovation, as the health care and medtech worlds turn – albeit slowly – to face...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.